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Marked Response to VNS in
a Post-Cingulotomy Patient:
Implications for the Mechanism
of Action of VNS in TRD
Charles R. Conway, MD, Mehret D. Gebretsadik MDc, and Richard D. Bucholz, MDd

ABSTRACT

FOCUS POINTS

Treatment-resistant major depression (TRMD,

• New, more invasive, treatments, (eg, vagus
nerve stimulation [VNS], deep brain stimulation),
are evolving for the treatment of refractory illnesses in psychiatry.
• VNS is Food and Drug Administration approved
for treatment augmentation in severe, treatment-refractory depression. Studies suggest that
the antidepressant effects of VNS are typically
delayed by months.
• Studies demonstrate that electroconvulsive therapy (ECT) and VNS can be safely administered
at the same time. Clinical experience and case
reports suggest that ECT and VNS may have
synergistic effects, (ie, patients who responded
poorly to ECT in the past may respond better to
this treatment after VNS implantation).

major depressive disorder that fails to respond
to numerous therapies) is a relatively common
and clinically challenging disorder. In many cases,
the most severely affected TRMD patients have
received surgical intervention (subcaudate tractotomy, limbic leucotomy, anterior capsulotomy,
and anterior cingulotomy). New treatments, including vagus nerve stimulation (VNS) and deep brain
stimulation, have emerged to treat individuals
with TRMD. We describe the case of a woman, 53
years of age, with a long and sustained history
of TRMD (33 years), which was unresponsive to
numerous treatments (multiple pharmacothera-

Her depression improved markedly, and it has

pies, psychotherapy, electroconvulsive therapy

remained in sustained remission for 3.5 years.

[ECT]). Additionally, her TRMD failed to respond

This case suggests a potential synergistic effect of

to a bilateral anterior cingulotomy. She underwent

VNS and ECT, as well as provides possible clues to

placement of a cervical vagus nerve stimulator

the neural circuitry of VNS in TRMD.

and a brief course of ECT (3 unilateral treatments).
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INTRODUCTION
Treatment-resistant major depression (TRMD) is
a variation of major depressive disorder in which
patients fail to respond to numerous treatments
(typically antidepressants with augmentation strategies and psychotherapy).1 In many patients with
TRMD, a variety of treatments, delivered singly or
in combination, including pharmacotherapies, psychotherapies, and electroconvulsive therapy (ECT),
fail to provide an adequate response. Psychiatry
has begun to explore more invasive treatments
for TRMD, including vagus nerve stimulation
(VNS),2 which was approved by the Food and Drug
Administration as an adjunctive antidepressant
therapy in 2005, and deep brain stimulation (DBS).
DBS has been approved for compassionate use
in obsessive-compulsive disorder and is currently
experimental for TRMD.3,4 In some severe cases,
surgical interventions are used, including subcaudate tractotomy, limbic leucotomy, anterior capsulotomy, and anterior cingulotomy.5 Unlike VNS
and DBS, these neurological surgeries involve creation of a lesion. In the case of a complete bilateral
cingulotomy (as described here), this lesion would
limit communication between the more anterior
and posterior portions of the cingulum bundle.
We describe the case of a TRMD patient whose
depression did not respond to aggressive pharmacotherapy, psychotherapy, bilateral anterior cingulotomy, or ECT, but which remitted when treated
with VNS in combination with ECT.

CASE REPORT
Ms M, a Caucasian woman, 53 years of age,
had TRMD of 33 years duration, and posttraumatic
stress disorder (PTSD) related to sexual trauma
that occurred around 20 years of age. Her depression began in her early teens and resulted in
multiple psychiatric hospitalizations and several
serious suicide attempts during her early twenties. She denied being depression-free for >30
consecutive days, alternating between “severely
depressed” and “mildly depressed” for her
entire adult life. She had no history of psychosis
or manic episodes. She reported limited anxiety
symptoms, predominantly PTSD-related (recurrent flashbacks and avoidance), although she
reported that these symptoms had not impaired
her functioning during the previous 10 years. Her
depressive symptoms were primarily characterized by low mood, anhedonia, anorexia, weight
loss, helplessness, hopelessness, excessive guilt,
and suicidal ideation. She had an extensive famCNS Spectr 16:6

ily history of depression, including a brother who
committed suicide. She denied use of illicit drugs
but reported a history of alcoholism that was 8
years in sustained remission. Her medical history
was remarkable for hypothyroidism (controlled),
fibromyalgia, epilepsy (controlled), and estrogen-replacement hormone therapy for oophorectomy for uterine cancer. The patient began having
seizures following a closed head trauma which
occurred at 46 years of age (her depression preceded her epilepsy). She reported an average of
2 seizures/year (tonic-clonic) from 46–53 years of
age, and she reports that she does not recollect
her depression being any worse after the seizures
than before.
Ms M’s pharmacotherapy treatment history for
TRMD was extensive. Over the previous 30 years,
she had been treated with various combinations of
2–5 antidepressants and numerous augmentation
agents. She had failed adequate dose-duration
antidepressant trials with several different classes
of antidepressant including selective serotonin
inhibitors (citalopram, paroxetine, fluvoxamine,
and escitalopram), tricyclic antidepressants (imipramine, amitryptyline), serotonin-norepinephrine
reuptake inhibitors (venlafaxine extended release,
duloxetine), buproprion, nefazodone, as well as
antidepressant augmentation trials with lithium,
aripiprazole, and olanzapine. She had multiple
courses of ECT (bilateral and unilateral) from
1970–2006, with generally limited immediate benefit and no sustained or long-term benefit. In 1981,
she underwent bilateral anterior cingulotomy for
TRMD, which had no effect on depressive symptoms. She attempted suicide on several occasions
after the cingulotomy. In 1983 she underwent a
course of bilateral ECT (10 treatments) with no
response. Two years later, another course of 10
bilateral ECT treatments also failed.
With regards to history of Diagnostic and
Statistical Manual of Mental Disorders, Fourth
Edition axis II pathology: none of her outpatient
records lists her as having an Axis II diagnosis.
Two psychiatric hospitalizations (1999 and 2000)
listed the diagnosis of “borderline personality disorder”; a subsequent hospitalization (2005) listed
“rule out borderline personality disorder”. She
underwent a Minnesota Multiphasic Personality
Inventory assessment in 2000, while hospitalized,
which concluded: “nonspecific findings—marked
anxiety, neediness, feelings of inadequacy, and
ruminations over past trauma.”
In late 2005 and early 2006 Ms. M failed another
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three month antidepressant combination trial:
duloxetine (90 mg QD) combined with quetiapine
(300 mg HS) and lithium (300 mg TID), as well as
topiramate (200 mg QHS) for epilepsy. In March
2006, having failed an extensive list of antidepressant and mood stabilizers, Ms M underwent
implantation of a VNS device for TRMD. Her previously described medications (ie, duloxetine, quetiapine, lithium, and topiramate) were unchanged.
VNS was initially ineffective, with her depression
(suicidal thoughts) resulting in a psychiatric hospitalization in May 2006. While in hospital, with
VNS ongoing, she underwent three unilateral ECT
treatments (VNS was temporarily deactivated
only during the interval in which she received the
ECT treatments), with considerable acute antidepressant benefit. At discharge, medications were
duloxetine (60 mg QD), temazepam (15 mg QHS),
and quetiapine (400 mg QHS).
After discharge, the patient experienced continued improvement in her depressive symptoms.
In June of 2006, she reported that her depression
was “much better,” and that her core primary
symptoms (anhedonia, decreased energy, hopelessness, helplessness, suicidal ideation) were
“gone.” At this time, quetiapine was discontinued
and zolpidem (for sleep) was added; otherwise,
only limited dose adjustments occurred during the subsequent months. Three and one-half
years later, she remains depression-free with no
residual depressive symptoms. During a recent
(December 2009) assessment, she scored 4 on the
Montgomery-Åsberg Depression Rating Scale,

which is consistent with depression remission.
At that time, she reported stable mood, good
sleep and appetite, social activity, good energy,
and motivation. In addition to VNS, her medications were duloxetine (60 mg PO QD), temazepam
(15 mg QHS), and zolpidem (10 mg QHS). She
also continued to participate in weekly cognitive
behavioral psychotherapy sessions, which began
five years ago. Additionally, she reports she has
not had any seizures following the implant of her
VNS device.
A high resolution computed tomography (CT
scan; Figure 1), acquired using a General Electric
LightSpeed VCT 64-Slice CT scanner (30 cm FOV,
no gantry tilt, 1024 x 1024 matrix, 1.5 mm slice
thickness) was obtained following placement of
VNS. Review of the CT scan and comparison to
standard brain atlases demonstrates a bilateral
lesions (from the 1981 cingulotomy surgery) in the
mid-portion of the cingulate gyrus with complete
obliteration of the structure in the superior inferior
and medial lateral dimensions.

DISCUSSION
This case report highlights a woman, now 56
years of age, with a lifelong history of profound
and debilitating TRMD characterized by numerous failed antidepressant medication trials, failed
ECT trials (both before and after cingulotomy),
and failed bilateral anterior cingulotomy, who has
experienced sustained remission of her TRMD
after VNS and a brief course (3 treatments) of ECT.
This case also highlights the potential synergis-

FIGURE 1.

Three different high resolution CT views of the cingulotomy lesion*

Panel A: Coronal view of the cingulotomy lesion demonstrating the near-complete superior-inferior ablation of the cingulate gyrus. Panel B: sagittal view of the medial surface
of the left hemisphere. Note the near complete transection of the cingulate extending from the superior surface to the corpus callosum. Panel C: An oblique view leaving skull
in place with lesion area highlighted in green. CT images acquired using a General Electric LightSpeed VCT 64-Slice CT scanner (30 cm FOV, no gantry tilt, 1024 x 1024 matrix,
1.5 mm slice thickness). CT images created using the Dextroscope® platform (Volume Interactions, Bracco Industries, Buckinghamshire, UK).
* Arrows denote the edges of cingulotomy lesion.
Conway CR, Gebretsadik MD, Bucholz RD. CNS Spectr. 2011.
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tic effect of VNS and ECT and allows for consideration of the neural pathways that may be essential
for a VNS response in TRMD, including the fact
that a completely transected anterior cingulate did
not prevent an antidepressant response to VNS.
Several articles describe the concomitant use of
ECT with VNS.6-8 ECT is not contraindicated in VNS,
but it is recommended that the device be deactivated during the ECT procedure to avoid potential complications involving cardiac or pulmonary
side effects.6 Some reports have suggested that
ECT and VNS may have a synergistic antidepressant effect.7,8 Our group has observed a similar antidepressant synergistic effect between VNS and ECT
in 3 cases as well (patients with lifelong histories of
requiring recurrent ECT, no longer requiring ECT as
frequently or requiring fewer ECT with the addition
of VNS). Sharma and colleagues 8 described two
patients (unipolar, bipolar depression) for whom
ECT had previously been unsuccessful. In both
patients, VNS, was initially unsuccessful until ECT
was reintroduced. It is also possible, in the case
described above, that the ECT simply coincided
with the patient’s response to VNS.
Demonstrating a direct causal relationship
between our patient’s sustained depression remission and VNS is not possible. Her history, however,
lacked any sustained antidepressant response
to any treatment. Before she received VNS, ECT
had not previously elicited a response. Although
some patients may experience an acute antidepressant response with only 3 ECT treatments, the
typical recommended effective “dose” of ECT, in
order to sustain the antidepressant response, is >3
treatments.9,10 Her initial early response to ECT, as
well as her sustained euthymia suggest that VNS
may have played a synergistic role with ECT. Ms.
M is currently depression-free, and has been for
4 years. Before receiving VNS, she reported no
depression-free period >1 month over her entire
life. Sackeim and colleagues11 studied the effectiveness of ECT in TRMD in which ECT had been discontinued, and they reported a very high relapse
rate (~70% at 1 year).
VNS has well-established efficacy in treatment-resistant epilepsy. Additionally, there is a
clear association between epilepsy and depression; hence it is possible that the patient’s partially-controlled epilepsy was contributing to her
depression.12 However, her depressive symptoms
(including hospitalizations and suicide attempts)
clearly preceded her traumatic epilepsy onset. It
is noteworthy that in addition to her depression
CNS Spectr 16:6

resolution, the patient also reports no further seizures following VNS implantation.
This case report may provide some key insights
into the critical neuroanatomical network components “required” for successful VNS treatment
in TRMD. The mechanism of action of VNS in
TRMD, as in epilepsy, is incompletely understood.
There is evidence that the effects of VNS on the
brain systems associated with mood are mediated both through primary brainstem nuclei projections (dorsal raphe, locus ceruleus, nucleus
tractus solitarius) and limbic system and direct
cortical pathways.13,14 Current models of depression hypothesize that depression represents a
dysregulation of several interconnected structures
in the frontal and limbic circuitry. 15-17 Key structures in this network include the prefrontal cortex
(medial, orbital, and dorsolateral), the amygdala,
the cingulate cortex, the hippocampus, striatum,
dorsal thalamus, and the hypothalamus. Many of
these structures intersect with the upstream afferent pathway of the vagus (Figure 2).
The cingulate cortex, fully transected in Ms. M’s
case, is considered a pivotal region in depression
neuroimaging studies. Visual inspection of the high
resolution CT scans (Figure 1) demonstrates that
the patient’s cingulate gyrus was transected at the
junctional region of the dorsal anterior cingulate
and the mid-cingulate. The transection occurred
well forward of the posterior cingulate cortex.
The cingulate (and underlying cingulum bundle)
is a critical structure in mood disorders. Structural
neuroimaging studies have demonstrated a reduction in gray matter volume in the left subgenual
anterior cingulate in individuals with depression.1820
Functional neuroimaging studies of the subgenual anterior cingulate cortex (Brodmann’s area [BA]
25) in depression have also shown this region to
be hypometabolic compared with non-depressed
controls.20 Other studies have demonstrated that
when corrected for the volume loss occurring in
this region with depression, BA 25 is actually hypermetabolic compared with nondepressed controls.21
Further, numerous treatment modalities, including medications,22 DBS,3 and sleep deprivation23
have demonstrated decreased metabolism of BA
25. More dorsal regions of the cingulate also have
been identified as involved in depression. Studies
have found that the dorsal anterior cingulate (dorsal to the corpus callosum and posterior to the genu
of the corpus callosum) also undergoes change
with depression: positron-emission tomography
imaging studies assessing antidepressant and DBS
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antidepressant response demonstrate increased
activation of this region.24,25
How might activation of the left vagus affect the
fronto-limbic mood circuitry? Upstream vagal projections synapse with anterior components of these
fronto-limbic circuits: most of the upstream afferent fibers of the vagus travel via the nucleus tractus solitaries (NTS).13 Fibers from the NTS project
to the central nucleus of the amygdala as well as
the nucleus accumbens. Additionally, animal models demonstrate the NTS, synapsing through the
parabrachial nucleus, also send projections to the
thalamus, the amygdala (particularly the central
nucleus of the amygdala, but also the basolateral
and other amygdalar nuclei), the anterior insula,
and infralimbic cortex, lateral prefrontal cortex,
and other cortical regions.13,26 Of note, the predominance of upstream vagal afferent pathways target
regions in the anterior/temporal portions of these
circuits (ie, amygdala, nucleus accumbens, insula,
and prefrontal cortex). The connections between

these regions would have been spared in the cingulotomy described in this case report (location of
surgical lesion depicted in Figure 3).
Neuroimaging studies of VNS in TRMD demonstrate that most of the acute effects of VNS in
TRMD occur in anterior and temporal regions.27-30
These regions include the anterior cingulate, the
insular region, lateral and medial prefrontal cortex, and orbitofrontal cortices.
Given the known neuroanatomy and evidence
from neuroimaging studies, two distinct (though
by no means exclusive) methods by which VNS
acts on the fronto-limbic mood circuitry emerge:
amygdalar and lateral orbital-insular synaptic
pathways. The amygdala is known to have extensive cortical projections, including the rostral
insula and temporal pole; however, the strongest
of these connections are with the medial prefrontal cortex rostral and ventral to the genu of the
corpus callosum.17 Similarly, vagal projections to
the lateral orbital cortex (and adjacent anterior

FIGURE 2.

Intersection between the affarent vagal pathway and the frontolimbic model of
depression15

Hippocampal
Subiculum
Amygdala
Basal N*
BNST

Central N

PVN
Lateral
Hypothalamus

Orbital/
Medical PFC
Thalamus*

Mediodorsal
Thalamus*

Ventral
Striatum*

Ventral
Pallidu

VTA
raphe*

PAG * DL, Lateral,
N Basialis Locus
Ceruleus* VTA

The model emphasizes how orbital and MPFC dysfunction leads to disinhibition of neural transmission through the amygdala (efferent paths from amygdala in red). Animal and
human neuroimaging studies have determined that the upstream pathways of the vagus have multiple intersections with the brain regions in this model (depicted by asterisks
alongside the structure). The majority of these regions are anteriorly positioned in the brain.
Figure adapted from Drevets WC, Price JL, Furey ML. Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression. Brain Struct Funct. 2008;213(1-2):93-118.
BNST=bed nucleus of the stria terminalis; Basal N=basal nucleus of the amygdala; Central N=central nucleus of the amygdala; PAG=periaqueductal gray; PVN=peraventricular
nucleus of the hypothalamus; VTA=ventral tegmental area; MPFC=medial prefrontal cortex.
Conway CR, Gebretsadik MD, Bucholz RD.. CNS Spectr. 2011.
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insular regions), which likely interact with medial
prefrontal regions, may be another mechanism
by which VNS acts in TRMD. In both instances,
these mechanisms of action seem to have minimal
involvement with the posterior limbic/paralimbic
circuitry and would not be affected by a bilateral
cingulotomy.
Understanding the anatomy of the cingulate
FIGURE 3.

Regional course of the cingulum fibers
in the anterior and posterior cingulate
cortex (Rhesus monkey) 31

The red vertical line represents approximate anterior margin of the cingulotomy lesion in this case. Using autoradiographic tracer injection studies Mufson
and Pandya31 were able to analyze the constituent white matter components
of the cingulum bundle. They found fibers arising from both the anterior and
posterior portions of the cingulate cortex projected into prefrontal cortex;
however, only fibers from the anterior portion (BA 24; Panel A) projected into
the insula and amygdala. In contrast, fibers originating from the posterior
cingulate cortex (BA 23; Panel B) did not project to these structures. These
tracer studies suggest that the principal direct communication between
cingulate cortex and other central components (eg, the AMG) of the frontallimbic circuitry implicated in mood disorders predominantly involves the more
anterior cingulate regions, which would not be affected by the cingulotomy
lesion (anterior margin of lesion depicted with dotted vertical line).
AMG=amygdala; CC=corpus callosum; CING BUN=cingulum bundle;
CING SUL=cingulate sulcus; PF=prefrontal cortex; INS=insula; p=pons;
PRH=parahippocampal gyrus; m=medulla; TH=thalamus; BA=Brodmann’s
area.
Conway CR, Gebretsadik MD, Bucholz RD. CNS Spectr. 2011.
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gyrus and underlying white matter (cingulum bundle) and the mechanism by which this structure
integrates with other components of the frontolimbic mood network may provide insights into
the reasons for the success of VNS in an individual
with a complete bilateral cingulotomy.
The anatomy and interconnections of fibers
making up the cingulate gyrus are very complex
and beyond the scope of this case report. Mufson
and Pandya 31 used an autoradiographic tracer
injection studies in Rhesus monkeys to analyze
the constituent white matter components of the
cingulum bundle. They found that most cingulum
fibers arise from the thalamus, the cingulate cortex itself, and association areas (Figure 3). Fibers
from all three origins project both rostrally and
caudally. Interestingly, fibers arising from both the
anterior and posterior portions of the cingulate
cortex projected into prefrontal cortex; however,
only fibers from the anterior portion (BA 24; Figure
3, panel A) project into the insula and amygdala.
In contrast, fibers originating from the posterior
cingulate cortex (BA 23; Figure 3, panel B) did not
project to these structures.31 These tracer studies
suggest that the principal direct communication
between cingulate cortex and other central components (eg, amygdala) of the frontal-limbic circuitry implicated in mood disorders predominantly
involves the more anterior cingulate regions.
On the basis of this case report, it appears that
direct communication between the posterior and
anterior cingulate is not necessary for VNS to be
efficacious in TRMD. Unlike DBS or VNS, a cingulotomy involves physically lesioning neuronal
pathways: a complete bilateral transection of the
cingulate cortex would likely cut at least much if
not all of the synaptic communication between
anterior and posterior components of the “default
mode system” (medial and dorsal prefrontal cortex and posterior cingulate cortex).32 Recent studies 33 suggest individuals with depression have
problems “shifting out” of the default mode system when challenged. Because the default mode
system has been associated with self-referential
function, it can be suggested that persistent activity in the system may be associated with rumination on self-related, possibly negative thoughts.

CONCLUSION
To our knowledge, this study is the first reported
case of a patient with a failed cingulotomy for
TRMD who subsequently experienced an antidepressant response to VNS. Based on the computed
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tomography confirmed, near-complete obliteration of the bilateral cingulate, this case suggests
an intact cingulum (in the anterior-posterior axis)
is not necessary to respond to VNS. Considering
that the most aggressive of treatments had failed
for Ms. M’s TRMD, this case study highlights the
potential efficacy of VNS in very treatment resistant clinical depression and emphasizes the need
for further studies to determine the mechanism of
action of VNS in TRMD. CNS
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